A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Baylor College of Medicine
Institut Claudius Regaud
Gilead Sciences
Otsuka Pharmaceutical Co., Ltd.
H. Lee Moffitt Cancer Center and Research Institute
Gustave Roussy, Cancer Campus, Grand Paris
Shanghai Pharmaceuticals Holding Co., Ltd
Centre Oscar Lambret
Janssen Research & Development, LLC
University of Illinois at Chicago
The Lymphoma Academic Research Organisation
Wake Forest University Health Sciences
Celgene
Allogene Therapeutics
Wake Forest University Health Sciences
Case Comprehensive Cancer Center
CEBIOTEX
Children's Hospital Medical Center, Cincinnati
Institute of Hematology & Blood Diseases Hospital, China
Pfizer
Baylor College of Medicine
University of California, San Diego
Prelude Therapeutics
Newave Pharmaceutical Inc
Lahore General Hospital
Blueprint Medicines Corporation
University Health Network, Toronto
Acerta Pharma BV
University of Pittsburgh
Kura Oncology, Inc.
Ruijin Hospital
University of Leeds
Massachusetts General Hospital
Alpha Tau Medical LTD.
Institut Curie
University of California, San Diego
Columbia University
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Novartis
Therapeutic Advances in Childhood Leukemia Consortium
Stanford University
Alexion Pharmaceuticals, Inc.
Novartis
University of Maryland, Baltimore
Merck Sharp & Dohme LLC
Wugen, Inc.
Takeda
Shandong First Medical University